What's hot at #AHA23? Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023. They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research. Trials Covered include: 00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack 06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial 12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial 16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation 10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes We value your opinion! Share your feedback by commenting on this page or sending us an email at [email protected].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related